Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | XDH | P47989 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17222094 | 0.83 | KDM4E (0.51) | GAAKDM4EGLALMNAALDH1A1 | |
| SCHEMBL70624 | 0.81 | GAA (0.67) | GAAKDM4EGLALMNAALDH1A1 | |
| SCHEMBL17649422 | 0.80 | ESR1 (0.56) | GAAKDM4EGLALMNAALDH1A1 | |
| SCHEMBL10749314 | 0.77 | KDM4E (0.62) | GAAKDM4EGLALMNAALDH1A1 | |
| SCHEMBL10293767 | 0.76 | SMN1; SMN2 (0.33) | ALDH1A1CYP1A2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL1422945 | 0.74 | KDM4E (0.58) | GAAKDM4EGLALMNAALDH1A1 | |
| SCHEMBL13804463 | 0.74 | GAA (0.58) | GAAKDM4EGLAALDH1A1MAPK1 | |
| SCHEMBL3551459 | 0.74 | GAA (0.58) | GAAKDM4EGLALMNAALDH1A1 | |
| SCHEMBL1197055 | 0.72 | GAA (0.56) | GAAKDM4EGLAALDH1A1MAPK1 | |
| SCHEMBL9918755 | 0.72 | GAA (0.56) | GAAKDM4EGLALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| WO-2010019930-A1 | UREA DERIVATIVES AS INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| EP-0986382-B1 | RAF KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1828169-A2 | UREA INHIBITORS OF MAP KINASES | Locus Pharmaceuticals, Inc. (US) | 2007-09-05 | — | — | EP | disclosed |
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION (US) | 2002-08-01 | — | — | US | disclosed |
| US-6344476-B1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION | 2002-02-05 | — | — | US | disclosed |
| US-20010006975-A1 | Raf kinase inhibitors | BAYER CORPORATION AND ONYX PHARMACEUTICALS WEST HAVEN, CT AND RICHMOND, CA, RESPECTIVELY | 2001-07-05 | — | — | US | disclosed |
| EP-0986382-A4 | RAF KINASE INHIBITORS | BAYER AG (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6187799-B1 | TREATING CANCEROUS CELL GROWTH MEDIATED BY RAF KINASE BY ADMINISTERING SPECIFIED COMPOUNDS, SUCH AS 2-(METHYOXYCARBONYL),3-((4-METHYLPHENYL)UREA),5-ALKYL-THIOPHENE | ONYX PHARMACEUTICALS | 2001-02-13 | — | — | US | disclosed |
| EP-1019040-A4 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER AG (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1019040-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | Bayer Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0986382-A1 | RAF KINASE INHIBITORS | Bayer Corporation (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998052558-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998052559-A1 | RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | MAPK1, MAP3K1, MAP3K7 | GAA 461/4885KDM4E 2456/4885GLA 1822/4885 |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | MAPK1, MAP3K1, MAP3K7 | GAA 461/4885KDM4E 2456/4885GLA 1822/4885 |
| US-20100063088-A1 | Raf Kinase Inhibitors | BRAF, RAF1, ARAF | GAA 2980/4885KDM4E 2074/4885GLA 3280/4885 |
| US-20120178780-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | GAA 2980/4885KDM4E 2074/4885GLA 3280/4885 |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | GAA 1948/4885KDM4E 2770/4885GLA 2883/4885 |
| US-20010006975-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | GAA 2980/4885KDM4E 2074/4885GLA 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.